BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22666513)

  • 1. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
    Hendrickx S; Inocêncio da Luz RA; Bhandari V; Kuypers K; Shaw CD; Lonchamp J; Salotra P; Carter K; Sundar S; Rijal S; Dujardin JC; Cos P; Maes L
    PLoS Negl Trop Dis; 2012; 6(5):e1664. PubMed ID: 22666513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains.
    Shaw CD; Imamura H; Downing T; Blackburn G; Westrop GD; Cotton JA; Berriman M; Sanders M; Rijal S; Coombs GH; Dujardin JC; Carter KC
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31658971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
    Hendrickx S; Boulet G; Mondelaers A; Dujardin JC; Rijal S; Lachaud L; Cos P; Delputte P; Maes L
    Parasitol Res; 2014 May; 113(5):1875-81. PubMed ID: 24615359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
    Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
    Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.
    Hendrickx S; Leemans A; Mondelaers A; Rijal S; Khanal B; Dujardin JC; Delputte P; Cos P; Maes L
    PLoS One; 2015; 10(10):e0140139. PubMed ID: 26469696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes.
    Maarouf M; Adeline MT; Solignac M; Vautrin D; Robert-Gero M
    Parasite; 1998 Jun; 5(2):167-73. PubMed ID: 9754313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Transplasma Membrane Electron Transport Chain in Wild and Drug-Resistant Leishmania donovani Promastigote and Amastigote.
    Debnath D; Hossain MA; Das M; Kabir A; Ibrahim M; Amin MN; Chowdhury A; Pervin R
    Acta Parasitol; 2019 Dec; 64(4):710-719. PubMed ID: 30941668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
    Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
    Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
    Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
    J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.
    Rastrojo A; García-Hernández R; Vargas P; Camacho E; Corvo L; Imamura H; Dujardin JC; Castanys S; Aguado B; Gamarro F; Requena JM
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):246-264. PubMed ID: 29689531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
    Hendrickx S; Beyers J; Mondelaers A; Eberhardt E; Lachaud L; Delputte P; Cos P; Maes L
    J Antimicrob Chemother; 2016 Jul; 71(7):1914-21. PubMed ID: 27084919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.
    Bhandari V; Sundar S; Dujardin JC; Salotra P
    Antimicrob Agents Chemother; 2014 May; 58(5):2580-5. PubMed ID: 24550335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes.
    Ephros M; Waldman E; Zilberstein D
    Antimicrob Agents Chemother; 1997 May; 41(5):1064-8. PubMed ID: 9145870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
    Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
    J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
    Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
    J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
    Subba Raju BV; Gurumurthy S; Kuhls K; Bhandari V; Schnonian G; Salotra P
    Parasitol Res; 2012 Oct; 111(4):1559-68. PubMed ID: 22752721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.
    Kulshrestha A; Singh R; Kumar D; Negi NS; Salotra P
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2916-21. PubMed ID: 21464251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent.
    Dumetz F; Cuypers B; Imamura H; Zander D; D'Haenens E; Maes I; Domagalska MA; Clos J; Dujardin JC; De Muylder G
    mSphere; 2018 Apr; 3(2):. PubMed ID: 29669889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.